Biolife Solutions Inc(BLFS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
AI-drawn chart patterns are for reference only.
Full metrics table
| Index | - | P/E | 39.93 | EPS (ttm) | 0.97 | Insider Own | 0.44% | Shs Outstand | 48.9M | Perf Week | - |
| Market Cap | 1.89B | Forward P/E | 133.14 | EPS next Y | -43.14% | Insider Trans | -84.79% | Shs Float | 48.7M | Perf Month | 4.78% |
| Enterprise Value | 1.82B | PEG | - | EPS next Q | 0.05 | Inst Own | 100.59% | Short Float | 8.21% | Perf Quarter | 32.73% |
| Income | 0.05B | P/S | 18.37 | EPS this Y | 304% | Inst Trans | - | Short Ratio | 3.56 | Perf Half Y | 79.58% |
| Sales | 0.10B | P/B | 4.49 | EPS next 5Y | - | ROA | 12.09% | Short Interest | 4.00M | Perf YTD | 59.68% |
| Book/sh | 8.59 | P/C | 22.92 | EPS past 3/5Y | 54.38% -55.02% | ROE | 13.15% | 52W High | -2.89% ($39.76) | Perf Year | 45.2% |
| Cash/sh | 1.68 | P/FCF | 232.9 | Sales past 3/5Y | -15.9% 14.88% | ROIC | 11% | 52W Low | 116.18% ($17.86) | Perf 3Y | 191.18% |
| Dividend Est. | - | EV/EBITDA | 284.26 | EPS Y/Y TTM | 981.57% | Gross Margin | 64.76% | Volatility(W/M) | 3.59% 2.78% | Perf 5Y | -3.81% |
| Dividend TTM | - | EV/Sales | 17.72 | Sales Y/Y TTM | 0.17% | Oper. Margin | 2.9% | ATR (14) | 1.13 | Perf 10Y | 2106.29% |
| Dividend Ex-Date | - | Quick Ratio | 7.14 | EPS Q/Q | 376.1% | Profit Margin | 46.35% | RSI (14) | 60.55 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.69 | Sales Q/Q | 11.98% | SMA20 | 4.12% ($37.08) | Beta | 1.75 | Target Price | $30.8 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/6 | SMA50 | 8.17% ($35.69) | Rel Volume | 0 | Prev Close | $38.61 |
| Employees | 155 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 2807.35% 2.41% | SMA200 | 45.03% ($26.62) | Avg Volume(3M) | 1.12M | Price | $38.61 |
| IPO | 1989/11/22 | Option/Short | No/No | Trades | 0 | Volume | - | Change | - |
🧬 BioLife Solutions (BLFS) is a U.S. healthcare company that develops, manufactures, and sells bioprocessing tools and services for the cell and gene therapy industry. Centered on its core biopreservation (cryopreservation) media products, the company combines controlled-rate freezing and thawing systems with storage services to provide an infrastructure that supports the entire production, shipping, and storage process for cell therapies.
Over the past 1 year, on the higher side
3% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
BLFS makes money exceptionally well
Of every $100 in sales, $2.90 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +304.0% this year.
Tap to view numbers
However, it looks expensive
For a company expected to earn $100 next year, you would pay $13,314. Peers typically go for $1,867.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is negative
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -3.8%. The S&P 500 did +47% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 100.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #24 of 53 in the industry
Based on market cap of $2B.
FAQ
BLFS belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
The market cap of BLFS is approximately $1.9B, ranking 2,081 within its sector.
BLFS has a P/E ratio of approximately 39.9x, which can be used to assess its valuation relative to the Healthcare sector average.
BLFS has recorded a 52-week high of $39.76 and a low of $17.86.